MedTrace Logo

Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects

NCT01311622 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-01-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether fostamatinib influences the plasma concentration of warfarin and changes its blood thinning effect, and to investigate how safe and tolerable it is when administered with warfarin.

Conditions

Interventions

DRUG

warfarin

2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart

DRUG

fostamatinib

2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days

Sponsors & Collaborators

Principal Investigators

  • James Ritter, BM BCh MRCP FRCP · Quintiles, Phase 1 Unit, London

  • Mark Layton, MD MRCP (UK) · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311622 on ClinicalTrials.gov